Long-Term Tx Adherence Low in Mild-to-Moderate Psoriasis

This article originally appeared here.
Share this content:
Long-Term Tx Adherence Low in Mild-to-Moderate Psoriasis
Long-Term Tx Adherence Low in Mild-to-Moderate Psoriasis

WEDNESDAY, Sept. 28, 2016 (HealthDay News) -- For patients with mild-to-moderate psoriasis, adherence to topical treatment is low, but an internet-based reporting intervention can improve adherence, according to a study published online Sept. 24 in the British Journal of Dermatology.

Hossein Alinia, from the Wake Forest School of Medicine in Winston-Salem, N.C., and colleagues examined how well medication is used in long-term topical treatment of psoriasis in an investigator-blinded prospective study involving 40 patients with mild-to-moderate psoriasis treated with topical fluocinonide over 12 months. Participants were randomized to standard-of-care or an internet-based reporting group in a 1:1 ratio. Medication Event Monitoring System caps were used to measure adherence.

The researchers found that 50 percent of participants discontinued treatment. The intervention group had greater adherence than the standard-of-care group (50 versus 35 percent; P = 0.08). Compared with the standard-of-care group, there was more improvement in the Psoriasis Area and Severity Index at month one (1.61 versus 0.12; P = 0.003), month three (2.50 versus 0.79; P = 0.025), and month 12 (3.32 versus 0.34; P = 0.038).

"Adherence to topical treatment is low in short term and decreased further in the long term, a considerable challenge for dermatologists to address," the authors write. "A reporting intervention may [be] one of the ways we can improve our patients' treatment outcomes."

Several authors disclosed financial ties to pharmaceutical companies, including Galderma, which partially funded the research.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »